Insight Wealth Strategies LLC Invests $201,000 in Eli Lilly and Company (NYSE:LLY)

Insight Wealth Strategies LLC bought a new position in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 222 shares of the company’s stock, valued at approximately $201,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Everpar Advisors LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $1,845,000. Allworth Financial LP lifted its stake in Eli Lilly and Company by 4.4% in the fourth quarter. Allworth Financial LP now owns 5,521 shares of the company’s stock valued at $3,218,000 after purchasing an additional 233 shares during the last quarter. Grimes & Company Inc. lifted its stake in shares of Eli Lilly and Company by 24.2% during the 4th quarter. Grimes & Company Inc. now owns 4,879 shares of the company’s stock valued at $2,844,000 after buying an additional 952 shares in the last quarter. Stratos Investment Management LLC increased its position in shares of Eli Lilly and Company by 2.4% during the fourth quarter. Stratos Investment Management LLC now owns 5,409 shares of the company’s stock valued at $3,153,000 after buying an additional 125 shares during the period. Finally, Stratos Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 6.7% in the fourth quarter. Stratos Wealth Advisors LLC now owns 5,228 shares of the company’s stock worth $3,048,000 after buying an additional 329 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 2.3 %

Eli Lilly and Company stock traded up $18.03 during trading on Tuesday, hitting $793.29. The company had a trading volume of 3,435,081 shares, compared to its average volume of 3,015,681. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. The stock has a market cap of $753.95 billion, a price-to-earnings ratio of 117.58, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a 1-year low of $450.58 and a 1-year high of $966.10. The company’s 50 day simple moving average is $870.16 and its 200-day simple moving average is $791.12.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.66%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now directly owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the sale, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of Eli Lilly and Company stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the transaction, the insider now owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,214,704 shares of company stock valued at $1,066,841,316. 0.13% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts recently commented on the company. The Goldman Sachs Group raised their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Bank of America restated a “buy” rating and set a $1,000.00 target price on shares of Eli Lilly and Company in a research report on Monday, June 24th. Guggenheim increased their target price on Eli Lilly and Company from $855.00 to $884.00 and gave the company a “buy” rating in a research report on Monday. Morgan Stanley reissued an “overweight” rating and set a $1,023.00 price objective on shares of Eli Lilly and Company in a report on Friday, July 5th. Finally, Truist Financial reissued a “buy” rating and issued a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $860.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.